Advanced search
1 file | 262.64 KB

Radiotherapy for renal-cell carcinoma

(2014) LANCET ONCOLOGY. 15(4). p.e170-e177
Author
Organization
Abstract
Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. There is an established biological rationale for the radiosensitivity of renal-cell carcinoma to stereotactic body radiotherapy based on the ceramide pathway, which is activated only when a high dose per fraction is given. Apart from the direct effect of stereotactic body radiotherapy on renal-cell carcinoma, stereotactic body radiotherapy can also induce an abscopal effect. This effect, caused by immunological processes, might be enhanced when targeted drugs and stereotactic body radiotherapy are combined. Therefore, rigorous, prospective randomised trials involving a multidisciplinary scientific panel are needed urgently.
Keywords
DOSE-PER-FRACTION, STEREOTACTIC BODY RADIOTHERAPY, POSTOPERATIVE RADIOTHERAPY, RADIATION-THERAPY, TUMOR RESPONSE, CANCER, APOPTOSIS, CERAMIDE, ABSCOPAL, METASTASES

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 262.64 KB

Citation

Please use this url to cite or link to this publication:

Chicago
De Meerleer, Gert, Vincent Khoo, Bernard Escudier, Steven Joniau, Alberto Bossi, Piet Ost, Alberto Briganti, et al. 2014. “Radiotherapy for Renal-cell Carcinoma.” Lancet Oncology 15 (4): e170–e177.
APA
De Meerleer, G., Khoo, V., Escudier, B., Joniau, S., Bossi, A., Ost, P., Briganti, A., et al. (2014). Radiotherapy for renal-cell carcinoma. LANCET ONCOLOGY, 15(4), e170–e177.
Vancouver
1.
De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal-cell carcinoma. LANCET ONCOLOGY. 2014;15(4):e170–e177.
MLA
De Meerleer, Gert, Vincent Khoo, Bernard Escudier, et al. “Radiotherapy for Renal-cell Carcinoma.” LANCET ONCOLOGY 15.4 (2014): e170–e177. Print.
@article{4403828,
  abstract     = {Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. There is an established biological rationale for the radiosensitivity of renal-cell carcinoma to stereotactic body radiotherapy based on the ceramide pathway, which is activated only when a high dose per fraction is given. Apart from the direct effect of stereotactic body radiotherapy on renal-cell carcinoma, stereotactic body radiotherapy can also induce an abscopal effect. This effect, caused by immunological processes, might be enhanced when targeted drugs and stereotactic body radiotherapy are combined. Therefore, rigorous, prospective randomised trials involving a multidisciplinary scientific panel are needed urgently.},
  author       = {De Meerleer, Gert and Khoo, Vincent and Escudier, Bernard and Joniau, Steven and Bossi, Alberto and Ost, Piet and Briganti, Alberto and FONTEYNE, VALERIE and Van Vulpen, Marco and Lumen, Nicolaas and Spahn, Martin and Mareel, Marcus},
  issn         = {1470-2045},
  journal      = {LANCET ONCOLOGY},
  keyword      = {DOSE-PER-FRACTION,STEREOTACTIC BODY RADIOTHERAPY,POSTOPERATIVE RADIOTHERAPY,RADIATION-THERAPY,TUMOR RESPONSE,CANCER,APOPTOSIS,CERAMIDE,ABSCOPAL,METASTASES},
  language     = {eng},
  number       = {4},
  pages        = {e170--e177},
  title        = {Radiotherapy for renal-cell carcinoma},
  url          = {http://dx.doi.org/10.1016/S1470-2045(13)70569-2},
  volume       = {15},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: